Nicholas C. DeVito

Also affiliated with Parker Institute for Cancer Immunotherapy, Duke Medical Center, Durham VA Medical Center, Duke Cancer Institute

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression”.

A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression

Science Immunology(2024)10.1126/sciimmunol.adi4191

N/A

0.729DataRank · unranked

128 citations

Yue Xue, Y‐Van Nguyen, Nicholas C. DeVito, X F Wang, Alisha Holtzhausen +4 more

Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy

Cell Reports(2021)10.1016/j.celrep.2021.109071

N/A

0.666DataRank · unranked

84 citations

Michael Sturdivant, Balamayooran Thievanthiran, Christine Xiao, Michael P. Plebanek, April K.S. Salama +6 more

Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti–PD-1 immunotherapy

Science Translational Medicine(2022)10.1126/scitranslmed.abq7019

N/A

0.606DataRank · unranked

56 citations

Nagendra Yarla, Tarek Haykal, Y‐Van Nguyen, Linda Cao, Michelle Ferreira +8 more

Role of dendritic cell metabolic reprogramming in tumor immune evasion

International Immunology(2020)10.1093/intimm/dxaa036

N/A

0.524DataRank · unranked

32 citations

Michael Sturdivant, Nicholas C. DeVito, Brent A. Hanks, Michael P. Plebanek

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy

Journal of Clinical Investigation(2020)10.1172/jci133055

N/A

0DataRank · unranked

251 citations

Kathy S. Evans, Nicholas C. DeVito, Michael P. Plebanek, Michael Sturdivant, Luke P. Wachsmuth +10 more

Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression

medRxiv(2025)10.1101/2025.10.06.25337175

N/A

0DataRank · unranked

0 citations

Nagendra Sastry Yarla, Kaylee Villareal, Y‐Van Nguyen, Linda Cao, Ernesto Pena Calderin +9 more

Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis

Cancers(2021)10.3390/cancers13194753

N/A

0DataRank · unranked

18 citations

Tarek Haykal, Linda Cao, Alisha Holtzhausen, Michael P. Plebanek, Nicholas C. DeVito +2 more

A SREBF2-dependent gene program drives an immunotolerant dendritic cell population during cancer progression

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.04.26.538456

N/A

0DataRank · unranked

3 citations

Yue Xue, Y‐Van Nguyen, Nicholas C. DeVito, Xueying Wang, Alisha Holtzhausen +5 more

Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.03.31.587500

N/A

0DataRank · unranked

1 citations

Y‐Van Nguyen, Michael Sturdivant, Michael P. Plebanek, Kaylee Howell, Nagendra Yarla +6 more